ARCT

Arcturus Therapeutics Holdings Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↑ 6/10
  • Value↓ 1/10
Arcturus Therapeutics Holdings sales and earnings growth
ARCT Growth
Good
  • Revenue Y/Y↓ -63.67%
  • EPS Y/Y↓ -11.86%
  • FCF Y/Y↑ 34.76%
Arcturus Therapeutics Holdings gross and profit margin trends
ARCT Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -143.80%
  • ROIC 5Y↓ -224.47%
Arcturus Therapeutics Holdings net debt vs free cash flow
ARCT Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Arcturus Therapeutics Holdings stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks